Liquid biopsy in bone sarcomas and identification of new biomarkers

[1]  Raghu Kalluri,et al.  The biology, function, and biomedical applications of exosomes , 2020, Science.

[2]  M. Mikuła,et al.  Signatures of circulating microRNA in four sarcoma subtypes , 2020, Journal of Cancer.

[3]  E. Pérez-Hernández,et al.  Metabolic profiling of serum in patients with cartilage tumours using 1H‐NMR spectroscopy: A pilot study , 2020, Magnetic resonance in chemistry : MRC.

[4]  M. Heymann,et al.  Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity , 2019, Theranostics.

[5]  S. Lee,et al.  Technologies for circulating tumor cell separation from whole blood , 2019, Journal of Hematology & Oncology.

[6]  S. M. Taghdisi,et al.  Exosomes, new biomarkers in early cancer detection. , 2019, Analytical biochemistry.

[7]  Zhen Wang,et al.  Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma , 2019, Journal of bone oncology.

[8]  P. Cartron,et al.  Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer , 2019, Biochemical pharmacology.

[9]  G. Ha,et al.  Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group , 2019, British Journal of Cancer.

[10]  M. Heymann,et al.  Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? , 2019, Drug discovery today.

[11]  Y. Zhang,et al.  Exosomes: biogenesis, biologic function and clinical potential , 2019, Cell & Bioscience.

[12]  C. Deng,et al.  Current Progresses of Exosomes as Cancer Diagnostic and Prognostic Biomarkers , 2019, International journal of biological sciences.

[13]  A. Godwin,et al.  Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. , 2018, Lab on a chip.

[14]  X. Xie,et al.  Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. , 2018, Cancer research.

[15]  B. Liu,et al.  Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery , 2018, Cancer management and research.

[16]  Li-li Li,et al.  Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV , 2018, International journal of oncology.

[17]  Shuai Zhang,et al.  MicroRNA-34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1 , 2018, Molecular medicine reports.

[18]  M. Heymann,et al.  Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.

[19]  Peng Su,et al.  Diagnostic and prognostic values of blood microRNA-Let7A for osteosarcoma , 2018, Journal of bone oncology.

[20]  Qiaojun He,et al.  KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells , 2018, Acta Pharmacologica Sinica.

[21]  B. Casini,et al.  Precision diagnostics of Ewing’s sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts , 2018, Therapeutic advances in medical oncology.

[22]  C. Garbutt,et al.  Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma , 2018, Cell Death & Disease.

[23]  P. Paterlini-Bréchot,et al.  EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas , 2018, Cancer biology & therapy.

[24]  M. López-Lázaro,et al.  The stem cell division theory of cancer. , 2018, Critical reviews in oncology/hematology.

[25]  R. Neumann,et al.  Circulating tumour-derived DNA in metastatic soft tissue sarcoma , 2018, Oncotarget.

[26]  S. Ferrari,et al.  Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients , 2018, Cancer management and research.

[27]  S. Avnet,et al.  Prominent role of RAB39A-RXRB axis in cancer development and stemness , 2018, Oncotarget.

[28]  Shulin Li,et al.  Cell-surface vimentin–positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors , 2017, Oncoimmunology.

[29]  M. Heymann,et al.  Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.

[30]  S. Avnet,et al.  Mesenchymal stroma: Role in osteosarcoma progression. , 2017, Cancer letters.

[31]  Shulin Li,et al.  Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. , 2017, Cancer letters.

[32]  Hua Zou,et al.  miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  V. Plagnol,et al.  Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection , 2017, Cancer medicine.

[34]  H. Bannasch,et al.  Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism , 2017, BMC Cancer.

[35]  Y. Lu,et al.  [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization]. , 2017, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[36]  Peng Zhang,et al.  MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway , 2017, Cellular Physiology and Biochemistry.

[37]  A. Viale,et al.  Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas. , 2017, JCO precision oncology.

[38]  A. Satelli,et al.  EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression , 2017, Oncotarget.

[39]  Chih-Hsin Tang,et al.  WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis , 2017, Oncotarget.

[40]  C. Garbutt,et al.  Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets , 2017, International journal of molecular sciences.

[41]  T. Ochiya,et al.  Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma , 2017, Oncotarget.

[42]  Chen Huang,et al.  A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical osteosarcoma patients , 2017, International journal of oncology.

[43]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[44]  Nathan C. Sheffield,et al.  Epigenetik erklärt Vielfalt von Krebs bei Kindern , 2017, TumorDiagnostik & Therapie.

[45]  R. Shen,et al.  The clinical significance of the Ezrin gene and circulating tumor cells in osteosarcoma , 2017, OncoTargets and Therapy.

[46]  D. Heymann,et al.  Cancer stem cells in osteosarcoma. , 2017, Cancer letters.

[47]  W. Guo,et al.  Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth , 2017, Cell Death & Disease.

[48]  Juanjuan Wen,et al.  Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma. , 2017, European review for medical and pharmacological sciences.

[49]  U. Dirksen,et al.  Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells , 2017, Oncogene.

[50]  Nathan C. Sheffield,et al.  DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma , 2017, Nature Medicine.

[51]  T. Lagerweij,et al.  Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression , 2017, Clinical Cancer Research.

[52]  G. Rosen,et al.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas , 2016, Clinical Sarcoma Research.

[53]  L. Pagliaro,et al.  Clinically Meaningful Use of Blood Tumor Markers in Oncology , 2016, BioMed research international.

[54]  H. Mankin,et al.  miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo , 2016, Molecular oncology.

[55]  C. Camps,et al.  Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? , 2016, Translational lung cancer research.

[56]  Xijing He,et al.  Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma. , 2016, Pathology, research and practice.

[57]  M. Heymann,et al.  Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.

[58]  D. Lian,et al.  Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma. , 2016, European review for medical and pharmacological sciences.

[59]  Jingang Tao,et al.  Upregulation of lncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway. , 2016, American journal of translational research.

[60]  Fenyong Chen,et al.  Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription , 2016, Tumor Biology.

[61]  Z. Duan,et al.  The roles and implications of exosomes in sarcoma , 2016, Cancer and Metastasis Reviews.

[62]  U. Dirksen,et al.  Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.

[63]  L. Alexandrov,et al.  Base changes in tumour DNA have the power to reveal the causes and evolution of cancer , 2016, Oncogene.

[64]  C. Scapulatempo-Neto,et al.  High Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients , 2016, PloS one.

[65]  G. Stein,et al.  Proteomic Analysis of Exosomes and Exosome‐Free Conditioned Media From Human Osteosarcoma Cell Lines Reveals Secretion of Proteins Related to Tumor Progression , 2016, Journal of cellular biochemistry.

[66]  G. Vunjak‐Novakovic,et al.  Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model , 2016, Theranostics.

[67]  O. P. Camargo,et al.  SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA , 2016, Acta ortopedica brasileira.

[68]  N. Zhang,et al.  Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing , 2016, PloS one.

[69]  P. Brousset,et al.  Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  D. Heymann,et al.  Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. , 2016, Clinical chemistry.

[71]  Meng Li,et al.  Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma , 2016, Tumor Biology.

[72]  Donghui Zheng,et al.  Genetic variants of lncRNA HOTAIR contribute to the risk of osteosarcoma , 2016, Oncotarget.

[73]  Leon W M M Terstappen,et al.  Challenges in circulating tumor cell detection by the CellSearch system , 2016, Molecular oncology.

[74]  W. Ren,et al.  Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children. , 2015, Genetics and molecular research : GMR.

[75]  Roman Kaliszan,et al.  Metabolomics for laboratory diagnostics. , 2015, Journal of pharmaceutical and biomedical analysis.

[76]  F. Wang,et al.  Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma. , 2015, International journal of clinical and experimental pathology.

[77]  B. Sartorius,et al.  Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma , 2015, Journal of bone oncology.

[78]  K. S. Hall,et al.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  P. Mukhopadhyay,et al.  Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis , 2015, PloS one.

[80]  Robin L. Jones,et al.  Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma , 2015, Rare tumors.

[81]  E. Rohren,et al.  Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. , 2015, JAMA oncology.

[82]  D. Placantonakis,et al.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells , 2015, Nature Communications.

[83]  Jie Tang,et al.  Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. , 2015, The Journal of surgical research.

[84]  L. Donehower,et al.  Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma , 2015, Cancer medicine.

[85]  Liwen Wu,et al.  Identification of a Plasma Four-microRNA Panel as Potential Noninvasive Biomarker for Osteosarcoma , 2015, PloS one.

[86]  Li-bin Yang,et al.  Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. , 2015, International journal of clinical and experimental pathology.

[87]  T. Triche,et al.  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression , 2015, Clinical Cancer Research.

[88]  Chun-Hao Tsai,et al.  CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. , 2015, Cancer letters.

[89]  Zheng Li,et al.  MicroRNA expression and its clinical implications in Ewing's sarcoma , 2015, Cell proliferation.

[90]  L. Ellis,et al.  Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression , 2014, Clinical Cancer Research.

[91]  Marcus R. Breese,et al.  Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. , 2014, The Journal of clinical investigation.

[92]  I. Amelio,et al.  TAp73 promotes anabolism , 2014, Oncotarget.

[93]  Piero Picci,et al.  Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis , 2014, PloS one.

[94]  P. Paterlini-Bréchot,et al.  Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion , 2014, OncoTargets and therapy.

[95]  L. Dai,et al.  Serum miR-9 as a prognostic biomarker in patients with osteosarcoma , 2014, The Journal of international medical research.

[96]  David M. Thomas,et al.  Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing , 2014, BMC Medical Genomics.

[97]  Carl R Walkley,et al.  Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? , 2014, Bone.

[98]  J. Huard,et al.  ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone. , 2014, Journal of cancer therapy.

[99]  A. Satelli,et al.  Universal marker and detection tool for human sarcoma circulating tumor cells. , 2014, Cancer research.

[100]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[101]  M. Heymann,et al.  Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? , 2013, Expert opinion on emerging drugs.

[102]  G. Raposo,et al.  First identification of Ewing's sarcoma‐derived extracellular vesicles and exploration of their biological and potential diagnostic implications , 2013, Biology of the cell.

[103]  L. Ouyang,et al.  A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma , 2013, Medical Oncology.

[104]  H. Jung,et al.  Continuous labeling of circulating tumor cells with microbeads using a vortex micromixer for highly selective isolation. , 2013, Biosensors & bioelectronics.

[105]  Wei Liu,et al.  CD133 expression in osteosarcoma and derivation of CD133⁺ cells. , 2013, Molecular medicine reports.

[106]  K. Nagashima,et al.  Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma , 2012, PloS one.

[107]  X. Liang,et al.  Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis , 2012, Diagnostic Pathology.

[108]  Man Yu,et al.  Cell-free circulating mitochondrial DNA in the serum: a potential non-invasive biomarker for Ewing's sarcoma. , 2012, Archives of medical research.

[109]  A. Testori,et al.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread? , 2012, Clinical & Experimental Metastasis.

[110]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[111]  B. Qian,et al.  Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma , 2012, Journal of surgical oncology.

[112]  Liangqun Rong,et al.  Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma , 2012, Molecular medicine reports.

[113]  N. Onishi,et al.  Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma , 2012, Molecular Cancer Research.

[114]  S. Rauser,et al.  CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients , 2011, Oncotarget.

[115]  S. Kharb,et al.  Serum Fluoride and Sialic Acid Levels in Osteosarcoma , 2011, Biological Trace Element Research.

[116]  M. Etchebehere,et al.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors – clinical and histological correlation , 2011, Clinics.

[117]  B. Song,et al.  Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. , 2011, Genetic testing and molecular biomarkers.

[118]  N. Akyürek,et al.  The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors , 2011, Pathology & Oncology Research.

[119]  I. McGonnell,et al.  Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy , 2011, Tumor Biology.

[120]  Xin Shi,et al.  Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[121]  D. LeBrun,et al.  FLI-1 Distinguishes Ewing Sarcoma From Small Cell Osteosarcoma and Mesenchymal Chondrosarcoma , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[122]  Wei Sun,et al.  Serum and urinary metabonomic study of human osteosarcoma. , 2010, Journal of proteome research.

[123]  Toshio Mori,et al.  Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. , 2010, Oncology reports.

[124]  A. Petrilli,et al.  Glutathione S-transferase polymorphisms in osteosarcoma patients , 2010, Pharmacogenetics and genomics.

[125]  A. Lopes,et al.  Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. , 2010, The Journal of bone and joint surgery. American volume.

[126]  Aaron R Cooper,et al.  Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma , 2010, Clinical Cancer Research.

[127]  N. Agarwal,et al.  CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. , 2010, Cancer research.

[128]  D. Herrero-Martín,et al.  The molecular pathogenesis of Ewing sarcoma , 2010, Cancer biology & therapy.

[129]  Yong Zhang,et al.  Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.

[130]  Weichun Guo,et al.  Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[131]  Naomi J Balamuth,et al.  Ewing's sarcoma. , 2010, The Lancet. Oncology.

[132]  G. Machak,et al.  Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas , 2009, Bulletin of Experimental Biology and Medicine.

[133]  P. Hogendoorn,et al.  Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes , 2009, Modern Pathology.

[134]  A. Patiño-García,et al.  Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. , 2009, Journal of proteome research.

[135]  Hye-Rim Park,et al.  Prognostic Implication of Immunohistochemical Runx2 Expression in Osteosarcoma , 2009, Tumori.

[136]  Y. Takakura,et al.  Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. , 2009, International journal of oncology.

[137]  S. Knuutila,et al.  Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors , 2009, Clinical Cancer Research.

[138]  E. Barillot,et al.  The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function , 2009, PloS one.

[139]  H Kovar,et al.  O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma , 2009, Oncogene.

[140]  S. Nelson,et al.  Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors , 2008, Laboratory Investigation.

[141]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[142]  W. Dong,et al.  Expression of c-kit Protein and Mutational Status of the c-kit Gene in Osteosarcoma and Their Clinicopathological Significance , 2008, The Journal of international medical research.

[143]  P. Picci,et al.  Prognostic Value of CCN3 in Osteosarcoma , 2008, Clinical Cancer Research.

[144]  A. Cleton-Jansen,et al.  Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas , 2005, The Journal of pathology.

[145]  A. Chan,et al.  Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  M. Heymann,et al.  The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. , 2019, Advances in experimental medicine and biology.

[147]  D. Heymann,et al.  Circulating Tumor Cells: The Importance of Single Cell Analysis. , 2018, Advances in experimental medicine and biology.

[148]  A. Rosenberg.  Bone Sarcoma Pathology: Diagnostic Approach for Optimal Therapy. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[149]  Zhanghua Li,et al.  Effects of altered CXCL12/CXCR4 axis on BMP2/Smad/Runx2/Osterix axis and osteogenic gene expressions during osteogenic differentiation of MSCs. , 2017, American journal of translational research.

[150]  Jianjun Lin,et al.  Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1. , 2016, American journal of translational research.

[151]  O. P. de Camargo,et al.  SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN EWING'S SARCOMA , 2016, Acta ortopedica brasileira.

[152]  M. Heymann,et al.  Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers , 2015, Journal of bone oncology.

[153]  Zhiming Liu,et al.  Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions , 2015, Clinical chemistry and laboratory medicine.

[154]  J. Peppercorn.  Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  Song Jin,et al.  Increased expression of serum gelsolin in patients with osteosarcoma. , 2012, Chinese Medical Journal.

[156]  A. D. Dei Tos,et al.  Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[157]  P. Meltzer,et al.  Molecular and Cellular Pathobiology Cancer Research Hypoxia Modulates EWS-FLI 1 Transcriptional Signature and Enhances the Malignant Properties of Ewing ' s Sarcoma Cells In vitro , 2010 .

[158]  O. Delattre,et al.  Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[159]  R. Grimer,et al.  Risk factors for survival and local control in chondrosarcoma of bone. , 2002, The Journal of bone and joint surgery. British volume.